9LG0 image
Deposition Date 2025-01-09
Release Date 2025-10-01
Last Version Date 2025-10-01
Entry Detail
PDB ID:
9LG0
Keywords:
Title:
Crystal Structure of Human Peroxiredoxin I in Complex with SAB
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Method Details:
Experimental Method:
Resolution:
1.81 Å
R-Value Free:
0.18
R-Value Work:
0.16
R-Value Observed:
0.16
Space Group:
P 21 21 21
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Peroxiredoxin-1
Gene (Uniprot):PRDX1
Mutagens:C52S/C83S
Chain IDs:A, B
Chain Length:175
Number of Molecules:2
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Augmentation of PRDX1-DOK3 interaction alleviates rheumatoid arthritis progression by suppressing plasma cell differentiation.
Acta Pharm Sin B 15 3997 4013 (2025)
PMID: 40893682 DOI: 10.1016/j.apsb.2025.06.006

Abstact

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation and joint damage, accompanied by the accumulation of plasma cells, which contributes to its pathogenesis. Understanding the genetic alterations occurring during plasma cell differentiation in RA can deepen our comprehension of its pathogenesis and guide the development of targeted therapeutic interventions. Here, our study elucidates the intricate molecular mechanisms underlying plasma cell differentiation by demonstrating that PRDX1 interacts with DOK3 and modulates its degradation by the autophagy-lysosome pathway. This interaction results in the inhibition of plasma cell differentiation, thereby alleviating the progression of collagen-induced arthritis. Additionally, our investigation identifies Salvianolic acid B (SAB) as a potent small molecular glue-like compound that enhances the interaction between PRDX1 and DOK3, consequently impeding the progression of collagen-induced arthritis by inhibiting plasma cell differentiation. Collectively, these findings underscore the therapeutic potential of developing chemical stabilizers for the PRDX1-DOK3 complex in suppressing plasma cell differentiation for RA treatment and establish a theoretical basis for targeting PRDX1-protein interactions as specific therapeutic targets in various diseases.

Legend

Protein

Chemical

Disease

Primary Citation of related structures